Table 8.
Contrast tests of mean scores of seven domains of symptom severity (in RQLQ-S) between groups at three post-tests (n = 240)
|
Activities
|
Sleep
|
Non-nose/non-eye symptoms
|
Practical problems
|
Nasal symptoms
|
Eye symptoms
|
Emotional
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Slope |
MD |
Slope |
MD |
Slope |
MD |
Slope |
MD |
Slope |
MD |
Slope |
MD |
Slope |
MD |
|
| (SE) | ( P ) | (SE) | ( P ) | (SE) | ( P ) | (SE) | ( P ) | (SE) | ( P ) | (SE) | ( P ) | (SE) | ( P ) | |
|
T2 |
|
|||||||||||||
| CS vs. placebo |
2.02 (0.95) |
-2.86 (0.004) |
1.78 (0.96) |
-2.04 (0.04) |
6.39 (2.13) |
-7.95 (<0.0005) |
3.77 (1.17) |
-3.21 (0.006) |
3.43 (1.43) |
-3.49 (0.02) |
2.93 (1.21) |
-2.90 (0.02) |
2.80 (1.15) |
-3.67 (0.001) |
| CS vs. YS |
-0.31 (0.95) |
-0.38 (0.69) |
0.47 (0.96) |
-0.30 (0.76) |
2.95 (2.12) |
-2.69 (0.20) |
1.10 (1.17) |
-0.49 (0.68) |
0.69 (1.43) |
-0.02 (0.99) |
0.96 (1.21) |
-0.69 (0.57) |
0.75 (1.15) |
-1.47 (0.20) |
| YS vs. placebo |
2.33 (0.95) |
-3.24 (0.002) |
1.31 (0.97) |
-1.74 (0.07) |
3.44 (2.13) |
-5.26 (0.01) |
2.68 (1.17) |
-2.72 (0.02) |
2.745 (1.44) |
-3.47 (0.02) |
1.98 (1.22) |
-2.22 (0.07) |
2.05 (1.15) |
-2.20 (0.06) |
|
T3 |
|
|||||||||||||
| CS vs. placebo |
2.93 (0.95) |
-3.76 (0.001) |
2.75 (0.96) |
-3.01 (0.002) |
7.32 (2.13) |
-8.88 (<0.0005) |
4.87 (1.17) |
-4.31 (<0.0005) |
5.44 (1.43) |
-5.50 (<0.0005) |
3.22 (1.21) |
-3.20 (0.008) |
3.01 (1.15) |
-3.97 (0.001) |
| CS vs. YS |
0.81 (0.95) |
-0.74 (0.44) |
1.38 (0.96) |
-1.21 (0.21) |
3.08 (2.12) |
-2.82 (0.18) |
2.07 (1.17) |
-1.46 (0.21) |
2.98 (1.43) |
-2.30 (0.11) |
1.47 (1.21) |
-1.20 (0.32) |
0.35 (1.15) |
-1.06 (0.36) |
| YS vs. placebo |
2.12 (0.95) |
-3.03 (0.003) |
1.38 (0.97) |
-1.80 (0.06) |
4.24 (2.13) |
-6.06 (0.004) |
2.81 (1.17) |
-2.85 (0.02) |
2.47 (1.44) |
-3.20 (0.03) |
1.76 (1.22) |
-2.00 (0.10) |
2.76 (1.15) |
-2.91 (0.01) |
|
T4 |
|
|||||||||||||
| CS vs. placebo |
3.18 (0.95) |
-4.01 (<0.0005) |
3.47 (0.96) |
-3.73 (<0.0005) |
6.20 (2.13) |
-7.76 (<0.0005) |
5.29 (1.17) |
-4.73 (<0.0005) |
6.70 (1.43) |
-6.76 (<0.0005) |
3.55 (1.21) |
-3.52 (0.004) |
3.17 (1.15) |
-4.04 (<0.0005) |
| CS vs. YS |
0.25 (0.95) |
-0.18 (0.85) |
1.29 (0.96) |
-1.13 (0.24) |
1.61 (2.12) |
-1.35 (0.53) |
1.37 (1.17) |
-0.76 (0.52) |
2.91 (1.43) |
-2.24 (0.12) |
1.18 (1.21) |
-0.91 (0.70) |
0.19 (1.15) |
-0.91 (0.43) |
| YS vs. placebo | 2.93 (0.95) | -3.83 (0.001) | 2.18 (0.97) | -2.60 (0.007) | 4.59 (2.13) | -6.41 (0.003) | 3.92 (1.17) | -3.97 (0.001) | 3.79 (1.44) | -4.52 (0.002) | 2.36 (1.22) | -2.61 (0.03) | 2.97 (1.15) | -3.12 (0.007) |
CS, Cure-allergic-rhinitis Syrup group; YS, Yu-ping-feng San group; RQLQ-S, Rhinoconjunctivitis Quality of Life Questionnaire Standard; MD, Mean difference between two groups; SE, Standard error in GEE test.